Patents by Inventor Herve Bazin

Herve Bazin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150198602
    Abstract: The present invention relates to an ex vivo method for determining the susceptibility of a patient suffering from cancer to respond to a therapeutic treatment based on the administration of an antibody specific for the HER2 protein, this method comprising the quantification of HER2-HER2 dimers in a tissue sample from said patient using the FRET technique. The invention also relates to a kit of reagents for implementing this method.
    Type: Application
    Filed: July 16, 2013
    Publication date: July 16, 2015
    Inventors: Fabrice Andre, Herve Bazin, Patrick Garnero, Gerard Mathis
  • Publication number: 20150185150
    Abstract: The subject matter of the invention is a method for measuring the luminescence of a long-life fluorescent compound present in a measuring medium, said medium containing a biological sample, characterized in that it comprises the following steps: a) introduction of a long-life fluorescent compound into the measuring medium, b) introduction, into the measuring medium, of a fluorescent marking agent, the absorption spectrum of which allows the excitation thereof at the same wavelength as that used to excite the long-life fluorescent compound, wherein said emission spectrum allows the measurement of the luminescence thereof at the same wavelength as that used to measure the luminescence of the long-life fluorescent compound, c) excitation of the measuring medium with a wavelength corresponding to an absorption peak of the long-life fluorescent compound, d) measurement of the luminescence emitted by the measuring medium immediately after excitation of said medium, mainly corresponding to the luminescence of the
    Type: Application
    Filed: February 22, 2012
    Publication date: July 2, 2015
    Applicant: CISBIO BIOASSAYS
    Inventors: Gerard Mathis, Herve Bazin
  • Patent number: 9024022
    Abstract: The invention relates to compounds of formula (I?): in which A, L2, M and B are as defined in the description. These compounds are substrates of O6-alkylguanine-DNA alkyltransferase and mutants thereof.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: May 5, 2015
    Assignee: Cis Bio International
    Inventors: Emmanuel Bourrier, Michel Laget, Laurent Lamarque, Norbert Tinel, Eric Trinquet, Hervé Bazin
  • Publication number: 20140242611
    Abstract: The invention relates to a method for quantifying a protein of interest expressed at the surface of a cell or else present in a tissue sample, said method comprising the use of two ligands capable of binding specifically to a domain of said protein.
    Type: Application
    Filed: July 4, 2012
    Publication date: August 28, 2014
    Applicant: CISBIO BIOASSAYS
    Inventors: Hervé Bazin, Gérard Mathis
  • Patent number: 8470523
    Abstract: The invention relates to a quantitative non-microscopic method of detecting intracellular interactions between biomolecules in living cells, in response to a biological or pharmacological stimulation, by a time-resolved proximate energy transfer effect between two members of a fluorescence donor/acceptor pair.
    Type: Grant
    Filed: September 4, 2006
    Date of Patent: June 25, 2013
    Assignee: CIS BIO International
    Inventors: Iris Pribilla, Hervé Bazin, Sraboni Ghose, Norbert Tinel, Michel Fink, Eric Trinquet, Gérard Mathis
  • Patent number: 8178704
    Abstract: The present invention relates to inositol phosphate derivatives, in which the inositol phosphate is substituted with one or two reactive groups G or one or two conjugated substances or molecules M, said reactive group(s) G or said substance(s) or molecule(s) M being linked to IP1 via a linkage group L, M being chosen from the following group: a tracer, an immunogen, a member of a binding partner pair, a solid support. Application: tools allowing the study of the inositol phosphate cycle and therefore, indirectly, the study of seven transmembrane domain receptors coupled to phospholipase C, receptors having a tyrosine kinase activity, and in general enzymes involved in the variations of the intracellular concentration of IP1.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: May 15, 2012
    Assignee: CIS Bio International
    Inventors: Hervé Bazin, Hervé Ansanay, Eric Trinquet, Gérard Mathis
  • Publication number: 20110236952
    Abstract: The invention relates to compounds of formula (I?): in which A, L2, M and B are as defined in the description.
    Type: Application
    Filed: September 22, 2009
    Publication date: September 29, 2011
    Applicant: CIS BIO International
    Inventors: Emmanuel Bourrier, Michel Laget, Laurent Lamarque, Norbet Tinel, Eric Trinquet, Hervé Bazin
  • Publication number: 20100143960
    Abstract: A subject matter of the invention is cyanine derivatives of formula: in which the dotted lines represent the atoms necessary for the formation of one or two fused aromatic rings, each ring comprising 5 or 6 carbon atoms; R1, R2, R3 and R4 represent, independently of one another: H; substituted or unsubstituted C1-C15 alkyl; C1-C6 alkoxy; (C2-C12)dialkylamino; C1-C6 alkoxycarbonyl; di(C2-C12)alkylamido; a substituted or unsubstituted aryl, arylalkyl or aryloxy group; a halogen atom; a nitro; an L1-W, L2-M, L2-A or L2-G group; R5 and R6 represent, independently of one another: substituted or unsubstituted C1-C15 alkyl; a substituted or unsubstituted aryl or arylalkyl group; an L1-W, L2-M, L2-A or L2-G group; X is chosen from: O, S or CR7R8; Y is chosen from: O, S or CR9R10; R7, R8, R9 and R10 independently represent: substituted or unsubstituted C1-C15 alkyl; substituted or unsubstituted aryl, arylalkyl or aryloxy; an L1-W, L2-M, L2-A or L2-G group; R7 and R8 and/or R9 and R10 can also together form a ring
    Type: Application
    Filed: March 7, 2008
    Publication date: June 10, 2010
    Applicant: CIS BIO INTERNATIONAL
    Inventor: Herve Bazin
  • Patent number: 7592006
    Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.
    Type: Grant
    Filed: April 7, 1998
    Date of Patent: September 22, 2009
    Assignee: Université Catholique de Louvain
    Inventors: Herve Bazin, Dominique Latinne
  • Publication number: 20090215106
    Abstract: The present invention relates to a quantitative non-microscopic method of detecting intracellular interactions between biomolecules, on living cells, in response to a biological or pharmacological stimulation, by a time-resolved proximate energy transfer effect between two members of a fluorescence donor/acceptor pair.
    Type: Application
    Filed: September 4, 2006
    Publication date: August 27, 2009
    Inventors: Iris Pribilla, Herve Bazin, Sraboni Ghose, Norbert Tinel, Michel Fink, Eric Trinquet, Gerard Mathis
  • Publication number: 20080261237
    Abstract: The present invention relates to inositol phosphate derivatives, in which the inositol phosphate is substituted with one or two reactive groups G or one or two conjugated substances or molecules M, said reactive group(s) G or said substance(s) or molecule(s) M being linked to IP1 via a linkage group L, M being chosen from the following group: a tracer, an immunogen, a member of a binding partner pair, a solid support. Application: tools allowing the study of the inositol phosphate cycle and therefore, indirectly, the study of seven transmembrane domain receptors coupled to phospholipase C, receptors having a tyrosine kinase activity, and in general enzymes involved in the variations of the intracellular concentration of IP1.
    Type: Application
    Filed: December 2, 2005
    Publication date: October 23, 2008
    Inventors: Herve Bazin, Herve Ansanay, Eric Trinquet, Gerard Mathis
  • Patent number: 7309567
    Abstract: The invention relates to a process for reducing the fluorescence quenching caused by the measuring medium, in a fluorescence assay for an analyte using at least one fluorescent label, characterized in that a fluorescent conjugate comprising an oligonucleotide bonded to a rare-earth metal cryptate is introduced into the measuring medium.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: December 18, 2007
    Assignee: CIS Bio International
    Inventors: Gerard Mathis, Herve Bazin, Eric Trinquet
  • Patent number: 7250167
    Abstract: A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when the immune response is mediated by the activation and proliferation of T-cells or natural killer cells.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: July 31, 2007
    Assignee: Université Catholique De Louvain
    Inventors: Hervé Bazin, Dominique Latinne, Pierre Gianello
  • Patent number: 7087384
    Abstract: The invention relates to a process for reducing the fluorescence quenching caused by the measuring medium in a fluorescence assay, by introducing into said medium of rare earth metal cryptates which are not very sensitive to this fluorescence quenching, said rare earth metal cryptates comprising at least one pyridine radical which is substituted one or more times or unsubstituted. The invention also relates to novel rare earth metal cryptates which are not very sensitive to the fluorescence quenching caused by the measuring medium.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: August 8, 2006
    Assignee: CIS bio international
    Inventors: Herve Autiero, Herve Bazin, Gerard Mathis
  • Publication number: 20050239073
    Abstract: The invention relates to a fluorescent entity comprising a fluorophore, with the exception of a rare earth metal cryptate, covalently attached to one or more oligonucleotide(s) or oligonucleotide analog(s) and comprising at least one functional group, introduced or generated on the fluorophore or one of the oligonucleotides or oligonucleotide analogs, allowing it to be coupled with a carrier molecule. The invention also relates to a fluorescent conjugate consisting of a fluorescent entity covalently attached to a carrier molecule.
    Type: Application
    Filed: June 6, 2003
    Publication date: October 27, 2005
    Inventors: Eric Trinquet, Fabrice Maurin, Herve Bazin, Gerard Mathis
  • Patent number: 6878552
    Abstract: The invention relates to a homogeneous method for detecting and/or determining by fluorescence a chemical or physicochemical interaction in a measuring medium, in which a rare-earth metal cryptate comprising a substituent is used, characterized in that the variation of at least one fluorescence characteristic of the rare-earth metal cryptate, induced by the change in the physicochemical properties of the substituent resulting from said interaction, is measured.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: April 12, 2005
    Assignee: Cis Bio International French Joint Stock Company
    Inventors: Gérard Mathis, Hervé Bazin
  • Publication number: 20050042718
    Abstract: A method for preparing antibodies including a) transfecting a cell line with a nucleic acid construction including in the same reading frame a nucleic sequence coding for a membrane protein and a nucleic sequence of interest coding for a polypeptide of interest, and b) preparing antibodies directed against the polypeptide of interest with cells prepared in step (a) or with their membranes.
    Type: Application
    Filed: September 29, 2003
    Publication date: February 24, 2005
    Applicant: Technopharm, a corporation of France
    Inventors: Herve Bazin, Yannick Nizet
  • Patent number: 6849258
    Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.
    Type: Grant
    Filed: July 18, 1997
    Date of Patent: February 1, 2005
    Assignees: Universite Catholique de Louvain, BioTransplant, Inc.
    Inventors: Hervé Bazin, Dominique Latinne, Ruth Kaplan, Thomas Kieber-Emmons, Christina E. Postema, Mary E. White-Scharf
  • Publication number: 20040092726
    Abstract: The invention relates to a process for reducing the fluorescence quenching caused by the measuring medium in a fluorescence assay, by introducing into said medium of rare earth metal cryptates which are not very sensitive to this fluorescence quenching, said rare earth metal cryptates comprising at least one pyridine radical which is substituted one or more times or unsubstituted.
    Type: Application
    Filed: December 16, 2002
    Publication date: May 13, 2004
    Inventors: Herve Autiero, Herve Bazin, Gerard Mathis
  • Patent number: 6692743
    Abstract: Although the mechanism of induction of apoptosis through antibody dependent cellular cytotoxicity (ADCC) mediated by NK cells is well understood, little is known about the fate of the reactive NK cells. Nevertheless, it has been shown that NK cells previously activated by IL-2, but not naive NK cells, died by apoptosis after Fc&ggr;RIIIa crosslinking, or after engagement in cytolytic functions. It is demonstrated that apoptosis of naive NK cells is also observed after stimulation with a rat IgG2b anti CD2 mAb (LO-CD2a/BTI-322) or anti HLAI (LO-HLA-1)mAb. The NK apoptosis is rapid (within minutes), Fas-ligand and mRNA synthesis independent and does not require a cell contact. The intracellular mechanism of NK cell apoptosis is calcium, PKC and PLA2 dependent but calcineurin and P13 kinase independent. We suggest that NK cell apoptosis results from the crosslinking on the same cell surface of CD2 or HLA-I molecules and Fc&ggr;RIIIa that exhibits a high affinity for the rat IgG2b isotype.
    Type: Grant
    Filed: May 4, 1999
    Date of Patent: February 17, 2004
    Assignee: Universite Catholique de Louvain
    Inventors: Herve Bazin, Dominique Latinne